• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vaccinex Inc (NQ: VCNX )

    3.160 -0.480 (-13.19%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vaccinex Inc

    < Previous 1 2 3 4 5 6 Next >
    Stocks That Hit 52-Week Lows On Wednesday
      On Wednesday, 345 companies set new 52-week lows. 
    Via Benzinga
    Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
    From Vaccinex, Inc.
    Via GlobeNewswire
    Why Is Vaccinex (VCNX) Stock Up 67% Today?
    Vaccinex (VCNX) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. 
    Via InvestorPlace
    Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Announces Private Placement with Commitments of $5.0 Million
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
    March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease 
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
    From Vaccinex, Inc.
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Tuesday
      On Tuesday, 74 companies achieved new lows for the year. 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
      Thursday's session saw 337 companies set new 52-week lows. 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    MarketBeat Week in Review – 2/6 - 2/10
    Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely 
    Via MarketBeat
    Topics Artificial Intelligence Economy
    Exposures Artificial Intelligence Economy Interest Rates
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Our coverage starts today with a look at the biggest pre-market stock movers traders will want to keep an eye on Wednesday! 
    Via InvestorPlace
    Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
    Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement. 
    Via Benzinga
    Should Investors Buy or Sell the Vaccinex Patent News?
    Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news? 
    Via MarketBeat
    Topics Intellectual Property
    Exposures Intellectual Property
    Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?
    Rubius Therapeutics (RUBY) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice. 
    Via InvestorPlace
    Why Is Bed Bath & Beyond (BBBY) Stock Down 32% Today?
    Bed Bath & Beyond (BBBY) stock is falling on Tuesday after the retailer revealed plans to raise $1 billion and warned of investing risks. 
    Via InvestorPlace
    Why Is Oak Street Health (OSH) Stock Up 36% Today?
    Oak Street Health (OSH) stock is on the rise Tuesday as investors react to a report that CVS (CVS) plans to take over the company. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    It's time to start the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday! 
    Via InvestorPlace
    The 3 Best Biotech Stocks Under $1 to Buy for January
    Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. 
    Via InvestorPlace
    Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
    Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform 
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Announces $3.8 Million Private Placement
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
    Continued Progress in Pepinemab Oncology and Neurology Clinical Programs 
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
    New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment Options 
    From Vaccinex, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Gainers Clearside Biomedical (NASDAQ:CLSD) stock rose 27.3% to $1.35 during Thursday's pre-market session. The market value of their outstanding shares is at $81.2 million. 
    Via Benzinga
    Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
    Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.